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RANK and RANK Ligand Expression
in Parotid Gland Carcinomas
Alessandro Franchi, MD,* Cecilia TavernaAQ2 ,* Antonella Simoni,* Monica Pepi,*
Giuditta Mannelli,w Martina Fasolati,w and Oreste Gallow
Abstract: Recently, it has been reported that deregulation of the
receptor activator of NFkB ligand (RANKL)/RANK signaling
axis results in salivary gland tumor development in a mouse
transgenic model. The aim of this study was to ascertain
RANKL and RANK protein expression in a series of primary
parotid gland carcinomas and to correlate it with clin-
icopathologic parameters. Formalin-fixed paraffin-embedded
tumor samples from 46 consecutive cases of parotid gland car-
cinoma were selected for this study. For comparison, we ex-
amined a group of 40 randomly chosen parotid gland adenomas,
including 20 pleomorphic adenomas, 10 myoepitheliomas, and
10 Warthin tumors. Immunohistochemical analysis for RANK
and RANKL was conducted on tissue microarrays. Overall, 33
carcinomas (71.7%) were scored as positive for RANK and 25
(54.3%) for RANKL. The expression of both RANK and
RANKL was significantly higher in carcinomas than in ad-
enomas as only 6 (15%) adenomas were positive for RANK,
and RANKL was negative in all benign tumors (P<0.001 for
both, Fisher exact test). Some histologic types, including sali-
vary duct carcinoma, mucoepidermoid carcinoma, and carci-
noma expleomorphic adenoma presented a high frequency of
RANK and RANKL expression. No significant correlation was
observed between RANK/RANKL expression and clinical pa-
rameters. Our study indicates that the expression of RANK and
RANKL in parotid gland neoplasms is associated with the ac-
quisition of a malignant phenotype and this pathway may rep-
resent an attractive therapeutic target in patients with parotid
gland carcinomas.
Key Words: parotid gland, carcinoma, RANK, RANKL, im-
munohistochemistry
(Appl Immunohistochem Mol Morphol 2016;00:000–000)
Salivary gland carcinomas are rare tumors representing<5% of all head and neck malignancies, with an es-
timated age-adjusted incidence rate of 11.95/1,000,000
person-years in the United States.1 The majority of sali-
vary gland carcinomas occur in the parotid gland, and
currently over 20 different histologic subtypes are recog-
nized in the WHO Classification, which show a highly
variable clinical behavior. Surgery remains the mainstay
for the treatment of parotid gland carcinomas, and ra-
diation therapy is administered on the basis of evaluation
of clinicopathologic risk factors. Chemotherapy may be
utilized as palliative treatment, although its efficacy has
not been proven in clinical trials.2,3 However, in the past
years, no significant improvement has been obtained in
the overall survival of patients affected by parotid gland
carcinomas. Therefore, there is urgent need of new
treatment strategies possibly based on the identification
of specific targets.
Recently, it has been reported that deregulation of
the receptor activator of NFkB ligand (RANKL)/RANK
signaling axis results in salivary gland tumor development
in a mouse transgenic model.4 Moreover, the RANKL/
RANK signaling axis could elicit an aggressive salivary
gland tumor phenotype at both the histologic and mo-
lecular level, whereas early blockade of RANKL/RANK
signaling markedly attenuated the development of ma-
lignant salivary gland neoplasms in this model.4 On the
basis of these results, the RANK/RANKL pathway may
represent a novel therapeutic target in salivary gland
carcinomas. As there are no data currently available on
the status of this signaling pathway in human salivary
tumors, we aimed to ascertain RANKL and RANK
protein expression in a series of primary parotid gland
carcinomas in this study. In addition, we examined the
impact of RANK and RANKL expression on patients’
outcome.
PATIENTS AND METHODS
Patients
A total of 46 consecutive patients treated at our
hospital for parotid gland carcinoma between 2001 and
2011 were selected for this study. In each case, all available
histologic slides were reviewed and tumors were classified
according to the 2005 WHO Classification scheme5 and
assigned to low-risk and high-risk categories as previously
described.6 The study group included 9 mucoepidermoid
carcinomas, 9 carcinomas expleomorphic adenoma, 7
adenoid cystic carcinomas, 5 acinic cell carcinomas, 4
salivary duct carcinomas, 3 squamous cell carcinomas, 3
myoepithelial carcinomas, 2 basal cell adenocarcinomas, 2
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adenocarcinomas NOSAQ3 , 1 undifferentiated carcinoma, and
1 epithelial-myoepithelial carcinoma. The salient clin-
icopathologic characteristics of this series are summarized
in Table 1. For comparison, we examined a group of 40
randomly chosen parotid gland adenomas, including 20
pleomorphic adenomas, 10 myoepitheliomas, and 10
Warthin tumors.
Immunohistochemistry
For tissue microarray construction, areas of interest
rich in non-necrotic tumor were identified on corre-
sponding hematoxylin and eosin-stained sections and
marked on the source paraffin block. The source block
was cored and a 1-mm core was transferred to the recip-
ient master block using the Beecher Tissue Microarrayer
(Beecher Instruments, Silver Spring, MD). Three cores
from different areas of the same tissue block were arrayed
for each case. Sections (5-mm thick) were obtained from
the block, which were stained with hematoxylin and eosin,
or utilized for the immunohistochemical analysis.
For immunohistochemical staining, tissue sections
(5 mm) were deparaffinized, hydrated, and after endoge-
nous peroxidase inactivation immunostained with
BenchMark Ultra stainer (Ventana, Tucson, AZ), and
revealed with iVIEW DAB detection kit, providing a
brown reaction product. Table 2 shows the antibody
source, dilution, and antigen retrieval protocol. After
completing the staining process, the slides were removed
from the autostainer, counterstained with hematoxylin,
dehydrated, and mounted with a permanent medium. As
a negative control, we substituted the primary antibody
with a Ventana dispenser filled with nonimmune serum at
the same concentration for each immunohistochemical
reaction. As a positive control, we used reactive bone and
bone fracture specimens.
The semiquantitative evaluation of the results of the
immunohistochemical studies was conducted considering
both the staining intensity and the percentage of positive
cells, as previously described.6 The staining intensity was
evaluated on a 4-point scale (0 to 3), and the proportion
of positive cells was evaluated according to the scale 0, 1
(1%), 2 (2% to 10%), 3 (11% to 30%), 4 (31% to 60%),
and 5 (100%).7 The 2 values were summed to obtain a
total score ranging between 0 and 8. For statistical
analysis, cases with score Z4 were considered positive.
Statistical Analysis
All statistical tests were performed using SPSS
software (release 12.0). Associations between categorical
variables were assessed by means of the w2 test. For
analysis of survival, the endpoints considered in this study
were rates of developing first local recurrence and rate of
any disease-related mortality. Local recurrence-free sur-
vival and disease-specific survival were modeled using the
Kaplan-Meier method and analyzed by the log-rank test.
w2 P<0.05 were considered significant.
RESULTS
The intensity score for RANKL was weaker than that
of RANK, whereas the proportion of positive cells was
similar for the 2 factors. Overall, 33 carcinomas (71.7%)
were scored as positive for RANK and 25 (54.3%) for
RANKL. The expression of both factors was significantly
higher in carcinomas than in adenomas as only 6 (15%)
adenomas were positive for RANK, whereas RANKL was
negative in all cases (P<0.001 for both, Fisher exact test).
The distribution of RANK and RANKL positivity
in carcinomas according to histologic type is shown
in Table 3. Although no significant difference was ob-
served, some histologic types, including salivary duct
carcinoma, mucoepidermoid carcinoma, and carcinoma
expleomorphic adenoma, presented a high frequency of
RANK and RANKL expression. Figure 1 illustrates the
results of the immunohistochemical studies in the main
histologic types. Moreover, high-grade tumors tended to
express RANKL more frequently than low-grade ones
(66.6% vs. 36.8%; P=0.07, Table 4).
In 5 of 9 cases of carcinoma expleomorphic ad-
enoma, we also examined RANK and RANKL ex-
pression in whole histologic sections including both the
benign and the malignant components of the tumor. In 2
cases, both the adenoma and the carcinoma were scored
as negative for RANK and RANKL. In 3 cases, the
malignant component of the tumor showed positive
staining for RANK whereas the adenoma was negative,
and an increase in RANKL expression from adenoma to
carcinoma was observed in 2 of these cases (Fig. 2).
As summarized in Table 4, no significant correlation
was observed between RANK/RANKL expression and
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TABLE 1. Summary of the Main Clinical Features of 46 Parotid
Carcinomas
Age (Mean) 61.3 y (Range, 26-87 y)
Sex (male:female) 31:15
T stage
I-II 27
III-IV 19
Lymph node metastasis 2
Distant metastasis 11
Local recurrence 5
Proportion disease free at 5 y (%) 72.1
Proportion surviving at 5 y (%) 73.9
TABLE 2. Features of the Antibodies Used in This Study
Antibody Clone and Provider Species and Dilution Antigen Retrieval
RANKL Polyclonal, Abcam, Cambridge, UK Rabbit, 1:2000 Citrate buffer, pH 6
RANK 64C1385, Abcam, Cambridge, UK Mouse, 1:200 Citrate buffer, pH 6
RANKL indicates receptor activator of NFkB ligand.
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clinical parameters, although the majority of patients with
facial nerve involvement (85.7%) had tumors positive for both
factors. Similarly, no correlation was found between the ex-
pression of the 2 factors and disease-free interval (P=0.13 for
RANK and P=0.76 for RANKL) as well as with overall
survival (P=0.18 for RANK and P=0.81 for RANKL).
DISCUSSION
To the best of our knowledge, this is the first analysis
of the immunohistochemical expression of RANK and
RANKL in parotid gland tumors. Our study indicates
that the expression of RANK and RANKL is associated
with the acquisition of a malignant phenotype, as we ob-
served that parotid carcinomas present a significantly
higher expression than adenomas. Accordingly, we also
observed an increased expression of both factors in the
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TABLE 3. Correlation Between Histologic Type and RANK and
RANKL Expression in 46 Salivary Gland Carcinomas
Histologic Type
RANK+
(%)
RANKL+
(%)
Mucoepidermoid carcinoma (N=9) 7 (77.8) 5 (55.6)
Carcinoma expleomorphic adenoma (N=9) 8 (88.9) 7 (77.8)
Adenoid cystic carcinoma (N=7) 2 (28.6) 1 (14.3)
Acinic cell carcinoma (N=5) 4 (80) 1 (20)
Salivary duct carcinoma (N=4) 4 (100) 3 (75)
Squamous cell carcinoma (N=3) 2 (66.7) 2 (66.7)
Myoepithelial carcinoma (N=3) 2 (66.7) 2 (66.7)
Basal cell adenocarcinoma (N=2) 0 0
Adenocarcinoma NOS (N=2) 2 (100) 2 (100)
Undifferentiated carcinoma (N=1) 1 (100) 1 (100)
Epithelial-myoepithelial carcinoma (N=1) 1 (100) 1 (100)
RANKL indicates receptor activator of NFkB ligand.
FIGURE 1. Immunohistochemical expression of RANK (A–C) and RANKL (D–F). Representative images from mucoepidermoid
carcinoma (A, D), adenoid cystic carcinoma (B, E), and salivary duct carcinoma (C, F).
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malignant component of 2 cases of carcinoma ex-
pleomorphic adenoma, and of RANK only in a further
example. Moreover, some histologic types presented a
high prevalence of positive cases, including salivary duct
carcinoma, mucoepidermoid carcinoma, and carcinoma
expleomorphic adenoma, although the differences were
not statistically significant, probably because of the high
number of histologic variants and the low number of cases
in each category.
These results are in keeping with recent ex-
perimental studies showing that activation of the
RANKL/RANK signaling axis in a transgenic mouse
model results in rapid tumor development in major sali-
vary glands.4 These tumors were histologically similar to
poorly differentiated mucoepidermoid carcinomas, and
expressed several molecular markers associated with
advanced-stage malignancies and poor prognosis.4
Moreover, RANKL elicited tumor cell proliferation with
overexpression of markers of cell division, including cy-
clin D1 and proliferation cell nuclear antigen.4
RANK and RANKL are members of the TNF su-
perfamily and are key regulators of immunity and bone
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TABLE 4. Correlation Between Clinicopathologic Features and
Expression of RANK and RANKL in 46 Parotid Gland
Carcinomas
RANK+N (%) P RANKL+N (%) P
Histologic grade
Low (19) 12 (63.1) 7 (36.8)
High (27) 21 (77.7) 0.3 18 (66.6) 0.07
T stage
I-II (27) 19 (70.3) 14 (51.8)
III-IV (19) 14 (73.6) 1.0 11 (57.8) 0.7
Local recurrence
No (41) 31 (75.6) 23 (56.1)
Yes (5) 2 (40.0) 0.15 2 (40.0) 0.65
Lymph node metastases
No (44) 31 (70.4) 24 (54.5)
Yes (2) 2 (100) 1.0 1 (100) 0.48
Distant metastases
No (35) 28 (80.0) 21 (60.0)
Yes (11) 5 (45.5) 0.67 4 (36.4) 0.30
Facial nerve involvement
No (39) 27 (69.2) 19 (48.7)
Yes (7) 6 (85.7) 0.65 6 (85.7) 0.11
RANKL indicates receptor activator of NFkB ligand.
FIGURE 2. Comparison of RANK (A, B) and RANKL (C, D) expression in carcinoma expleomorphic adenoma. A–C, Absent
expression in the adenoma. B–D, High expression in the malignant component.
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remodeling.8–10 This signaling system is involved in the
control of osteoclast activity and in the development of
skeletal disorders such as osteoporosis and bone meta-
stasis. The RANK/RANKL pathway is also involved in
the growth of giant cell tumor of bone.11 However, there
is increasing evidence that the RANK/RANKL system is
involved in the regulation of several key aspects of the
development of epithelial tissues such as the mammary
gland, and it is implicated in the acquisition of aggressive
malignant features in other epithelial tumors, including
breast and prostate carcinomas,12,13 renal cell carcino-
ma,14 and lung carcinoma.15 In particular, considering the
similarities between mammary gland tumors and salivary
gland tumors, with significant overlaps in their histo-
pathologic features and regulatory mechanisms, it is of
interest that expression studies in human breast carcino-
ma have shown that RANK protein expression is asso-
ciated with hormone receptor–negative status, high-
pathologic grade, and poor survival.16 In the present
study, no correlation could be found between RANK/
RANKL expression and clinical parameters of tumor
aggressiveness, including stage, facial nerve involvement,
nodal and distal metastases, as well as survival. This may
be due to the intrinsic variability of clinical behavior
among the several different histologic subtypes of parotid
gland carcinomas and the relatively small number of cases
analyzed.
In the recently reported preclinical mouse model,
early therapeutic targeting of the RANK/RANKL sig-
naling axis significantly attenuated salivary gland tumor
progression,4 suggesting that this pathway may represent
a novel area of therapeutic intervention in salivary gland
carcinomas. Denosumab, a monoclonal antibody directed
against RANKL, is currently used in the management of
osteoporosis, bone metastases, and giant cell tumor of
bone, mainly for its role of inhibitor of bone resorption
through its effects on osteoclastogenesis.17 However,
there is increasing evidence that inhibition of the RANK/
RANKL axis may offer new therapeutic chances in cancer
patients. Indeed, in a phase III clinical trial of patients
affected by lung cancer, Denosumab determined an in-
crease not only in bone metastasis–free survival but also
in overall survival,15 indicating a possible direct anti-
tumor effect of this drug. In addition, 1 patient with
metastatic adenocarcinoma of the lung with ALKAQ4 gene
rearrangement responded to treatment with Denosu-
mab.18 In this context, our preliminary results support the
hypothesis that targeting the RANK/RANKL signaling
pathway may represent a valid option to be tested either
alone or in combination with other therapies for the
treatment of parotid gland carcinomas. Further studies
on larger series of patients are needed to explore this at-
tractive hypothesis.
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